Protalix swings to Q2 profit of USD 3.8 million; revenue from selling goods rises 28.5% to USD 19.8 million

Reuters2026/08/12 10:51

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Protalix posts Q2 net income of USD 3.8 million, or USD 0.05 per share, versus USD 164,000 a year earlier.
Revenue from selling goods rises 28.5% to USD 19.8 million, driven mainly by higher sales of Elfabrio.
First-half net income totals USD 22.1 million, turning from a loss of USD 3.5 million; total revenue more than doubled to USD 53.6 million.
Cash, cash equivalents and short-term bank deposits end June at USD 40.7 million, cited as sufficient to fund operations including PRX-115 Phase 2.
2026 total revenue outlook maintained at USD 78 million-USD 83 million; PRX-115 Phase 2 top-line results expected in 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608120650PR_NEWS_USPR_____LN22768) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Protalix swings to Q2 profit of USD 3.8 million; revenue from selling goods rises 28.5% to USD 19.8 million

You may also like

Crypto prices